Skip to main content
    U

    Upstream Bio, Inc. (UPB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.15
    -0.63 (-22.66%)

    Market Cap: $152.38M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Upstream Bio, Inc. (UPB) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Upstream Bio reported revenue of $2.85M for the fiscal year ended Dec 31, 2025, up 20.4% from the year before. That year, net income was -$143.44M with a net margin of -5026.0%, operating cash flow was -$133.28M and free cash flow was -$133.44M. The quarter ended Sep 30, 2026 had revenue of $395.00K and net income of -$41.19M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$2.85M+20.4%100.0%-5618.8%-5026.0%
    Dec 2024$2.37M-0.4%100.0%-3281.2%-2650.0%
    Dec 2023$2.38M+96.4%100.0%-1685.5%-862.9%
    Dec 2022$1.21MN/A100.0%-1972.7%-1969.3%
    Annual, fiscal years ended Dec 2022 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022
    Revenue$2.85M$2.37M$2.38M$1.21M
    Cost of revenue$0$0$0$7.00K
    Gross profit$2.85M$2.37M$2.38M$1.21M
    Research and development$136.81M$62.97M$31.80M$18.66M
    Operating income-$160.36M-$77.76M-$40.11M-$23.91M
    Net income-$143.44M-$62.81M-$20.54M-$23.87M
    EBITDAN/A-$76.50M-$25.90M-$23.86M
    Fiscal years ended Dec 2022 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$395.00K$773.00K$1.03M$668.00K$683.00K$937.00K$566.00K$613.00K$607.00K$510.00K$640.00K$450.00K
    Gross profit$395.00K$773.00K$1.03M$668.00K$683.00K$937.00K$566.00K$613.00K$607.00K$510.00K$640.00K$450.00K
    Operating income-$43.38M-$42.37M-$43.62M-$46.17M-$37.83M-$44.35M-$32.01M-$26.32M-$18.89M-$17.54M-$15.01M-$14.33M
    Net income-$41.19M-$39.70M-$40.59M-$42.46M-$33.75M-$39.97M-$27.27M-$21.24M-$15.99M-$14.68M-$10.89M-$11.83M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $720.00K by $100.86M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022
    Total assets$353.77M$481.72M$117.20M$18.48M
    Current assets$351.80M$479.16M$117.00M$18.31M
    Cash and equivalents$101.58M$325.89M$25.83M$17.05M
    Total liabilities$14.00M$11.87M$9.39M$124.63M
    Short-term debt$720.00K$704.00K$45.00K$87.00K
    Shareholder equity$339.77M$469.85M-$123.13M-$106.16M
    Fiscal years ended Dec 2022 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$245.99M$281.17M$318.05M$353.77M$391.19M$420.52M$456.17M$481.72M$232.70M$244.51MN/A$117.20M
    Total liabilities$12.02M$10.21M$14.06M$14.00M$12.61M$11.78M$10.56M$11.87M$12.14M$391.12M-$107.81M$240.32M
    Cash and equivalents$47.42M$79.40M$96.72M$101.58M$72.16M$45.46M$71.31M$325.89M$32.95M$47.34MN/A$25.83M
    Shareholder equity$233.97M$270.96M$304.00M$339.77M$378.58M$408.74M$445.61M$469.85M-$160.31M-$146.61M$107.81M-$123.13M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022
    Operating cash flow-$133.28M-$59.17M-$37.93M-$19.02M
    Capital expenditures$165.00K$511.00K$144.00K$82.00K
    Free cash flow-$133.44M-$59.68M-$38.07M-$19.10M
    Investing cash flow-$93.48M-$59.48M-$82.84M-$82.00K
    Financing cash flow$2.44M$418.91M$129.55M$9.96M
    Fiscal years ended Dec 2022 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$54.23M-$35.62M-$47.85M-$30.63M-$22.24M-$39.24M-$41.16M-$19.61M-$13.96M-$8.04M-$17.56M-$16.11M
    Capital expendituresN/AN/A$0$54.00K$64.00K$47.00K$0$185.00K$326.00K$0$0$0
    Free cash flowN/AN/A-$47.85M-$30.68M-$22.30M-$39.29M-$41.16M-$19.80M-$14.29M-$8.04M-$17.56M-$16.11M
    Last 12 quarters

    Frequently Asked Questions About UPB

    What is Upstream Bio's annual revenue?

    Upstream Bio reported revenue of $2.85M for the fiscal year ended Dec 31, 2025.

    How fast is Upstream Bio's revenue growing?

    Revenue was up 20.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 33.0%.

    Is Upstream Bio profitable?

    No. Upstream Bio reported net income of -$143.44M for the fiscal year ended Dec 31, 2025, with a net margin of -5026.0%.

    How much free cash flow does UPB generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$133.28M minus capital expenditures of $165.00K produced free cash flow of -$133.44M.

    How much debt does Upstream Bio have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $720.00K and cash and equivalents of $101.58M.